Sarepta Therapeutics Appoints New CMO, Elects Directors
Ticker: SRPT · Form: 8-K · Filed: Jun 7, 2024 · CIK: 873303
Sentiment: neutral
Topics: leadership-change, board-of-directors, auditor-ratification
TL;DR
Sarepta just named a new CMO and added two directors to the board, plus stockholders approved the auditor.
AI Summary
Sarepta Therapeutics, Inc. announced on June 6, 2024, the appointment of Dr. Michael L. Johnson as Chief Medical Officer and the election of Dr. Johnson and Ms. Anne M. VanLent to its Board of Directors. The company also reported on the outcome of its 2024 Annual Meeting of Stockholders, where all nominated directors were elected and a proposal to ratify the appointment of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024, was approved.
Why It Matters
Key leadership changes and board appointments can signal strategic shifts or reinforce the company's direction in drug development and governance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance matters such as director elections and auditor ratification, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Sarepta Therapeutics, Inc. (company) — Registrant
- Dr. Michael L. Johnson (person) — Appointed Chief Medical Officer and elected to Board of Directors
- Ms. Anne M. VanLent (person) — Elected to Board of Directors
- PricewaterhouseCoopers LLP (company) — Independent registered public accounting firm
- June 6, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Sarepta Therapeutics?
Dr. Michael L. Johnson has been appointed as the new Chief Medical Officer of Sarepta Therapeutics.
Who were elected to the Board of Directors of Sarepta Therapeutics?
Dr. Michael L. Johnson and Ms. Anne M. VanLent were elected to the Board of Directors of Sarepta Therapeutics.
What was the outcome of the 2024 Annual Meeting of Stockholders regarding director elections?
All nominated directors were elected at the 2024 Annual Meeting of Stockholders.
Which accounting firm was ratified as Sarepta Therapeutics' independent auditor?
PricewaterhouseCoopers LLP was ratified as Sarepta Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2024.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is June 6, 2024.
Filing Stats: 819 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2024-06-07 16:45:31
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share SRPT Nasdaq Glo
Filing Documents
- d810236d8k.htm (8-K) — 38KB
- d810236dex101.htm (EX-10.1) — 7KB
- 0001193125-24-157458.txt ( ) — 164KB
- srpt-20240606.xsd (EX-101.SCH) — 3KB
- srpt-20240606_lab.xml (EX-101.LAB) — 17KB
- srpt-20240606_pre.xml (EX-101.PRE) — 11KB
- d810236d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Amendment No. 1 to the Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan 104 The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Sarepta Therapeutics, Inc. Date: June 7, 2024 By: /s/ Douglas S. Ingram Douglas S. Ingram President and Chief Executive Officer